[Translation] A Phase III, randomized study comparing talquetamab plus pomalidomide (Tal-P), talquetamab plus teclistamab (Tal-Tec), and investigator's choice of elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma who have received 1 to 4 lines of therapy, including an anti-CD38 antibody and lenalidomide
试验目的是比较Talquetamab联合泊马度胺或Talquetamab联合Teclistamab与Elotuzumab联合泊马度胺地塞米松或泊马度胺联合硼替佐米地塞米松的疗效
[Translation] The aim of the trial is to compare the efficacy of talquetamab plus pomalidomide or talquetamab plus teclistamab with that of elotuzumab plus pomalidomide dexamethasone or pomalidomide plus bortezomib dexamethasone.